Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

<p>Abstract</p> <p>Activating mutations in BRAF kinase are common in melanomas. Clinical trials with PLX4032, the mutant-BRAF inhibitor, show promising preliminary results in patients selected for the presence of V600E mutation. However, activating V600K mutation is the other most...

Full description

Bibliographic Details
Main Authors: Bacchiocchi Antonella, Cheng Elaine, Ariyan Stephan, Pavlick Anna C, Sznol Mario, Rubinstein Jill C, Kluger Harriet M, Narayan Deepak, Halaban Ruth
Format: Article
Language:English
Published: BMC 2010-07-01
Series:Journal of Translational Medicine
Online Access:http://www.translational-medicine.com/content/8/1/67
id doaj-4ee1ad6cb4764e85a1dcce6004e8e8a2
record_format Article
spelling doaj-4ee1ad6cb4764e85a1dcce6004e8e8a22020-11-24T22:21:51ZengBMCJournal of Translational Medicine1479-58762010-07-01816710.1186/1479-5876-8-67Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032Bacchiocchi AntonellaCheng ElaineAriyan StephanPavlick Anna CSznol MarioRubinstein Jill CKluger Harriet MNarayan DeepakHalaban Ruth<p>Abstract</p> <p>Activating mutations in BRAF kinase are common in melanomas. Clinical trials with PLX4032, the mutant-BRAF inhibitor, show promising preliminary results in patients selected for the presence of V600E mutation. However, activating V600K mutation is the other most common mutation, yet patients with this variant are currently excluded from the PLX4032 trials. Here we present evidence that a patient bearing the BRAF V600K mutation responded remarkably to PLX4032, suggesting that clinical trials should include all patients with activating BRAF V600E/K mutations.</p> http://www.translational-medicine.com/content/8/1/67
collection DOAJ
language English
format Article
sources DOAJ
author Bacchiocchi Antonella
Cheng Elaine
Ariyan Stephan
Pavlick Anna C
Sznol Mario
Rubinstein Jill C
Kluger Harriet M
Narayan Deepak
Halaban Ruth
spellingShingle Bacchiocchi Antonella
Cheng Elaine
Ariyan Stephan
Pavlick Anna C
Sznol Mario
Rubinstein Jill C
Kluger Harriet M
Narayan Deepak
Halaban Ruth
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
Journal of Translational Medicine
author_facet Bacchiocchi Antonella
Cheng Elaine
Ariyan Stephan
Pavlick Anna C
Sznol Mario
Rubinstein Jill C
Kluger Harriet M
Narayan Deepak
Halaban Ruth
author_sort Bacchiocchi Antonella
title Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
title_short Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
title_full Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
title_fullStr Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
title_full_unstemmed Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032
title_sort incidence of the v600k mutation among melanoma patients with braf mutations, and potential therapeutic response to the specific braf inhibitor plx4032
publisher BMC
series Journal of Translational Medicine
issn 1479-5876
publishDate 2010-07-01
description <p>Abstract</p> <p>Activating mutations in BRAF kinase are common in melanomas. Clinical trials with PLX4032, the mutant-BRAF inhibitor, show promising preliminary results in patients selected for the presence of V600E mutation. However, activating V600K mutation is the other most common mutation, yet patients with this variant are currently excluded from the PLX4032 trials. Here we present evidence that a patient bearing the BRAF V600K mutation responded remarkably to PLX4032, suggesting that clinical trials should include all patients with activating BRAF V600E/K mutations.</p>
url http://www.translational-medicine.com/content/8/1/67
work_keys_str_mv AT bacchiocchiantonella incidenceofthev600kmutationamongmelanomapatientswithbrafmutationsandpotentialtherapeuticresponsetothespecificbrafinhibitorplx4032
AT chengelaine incidenceofthev600kmutationamongmelanomapatientswithbrafmutationsandpotentialtherapeuticresponsetothespecificbrafinhibitorplx4032
AT ariyanstephan incidenceofthev600kmutationamongmelanomapatientswithbrafmutationsandpotentialtherapeuticresponsetothespecificbrafinhibitorplx4032
AT pavlickannac incidenceofthev600kmutationamongmelanomapatientswithbrafmutationsandpotentialtherapeuticresponsetothespecificbrafinhibitorplx4032
AT sznolmario incidenceofthev600kmutationamongmelanomapatientswithbrafmutationsandpotentialtherapeuticresponsetothespecificbrafinhibitorplx4032
AT rubinsteinjillc incidenceofthev600kmutationamongmelanomapatientswithbrafmutationsandpotentialtherapeuticresponsetothespecificbrafinhibitorplx4032
AT klugerharrietm incidenceofthev600kmutationamongmelanomapatientswithbrafmutationsandpotentialtherapeuticresponsetothespecificbrafinhibitorplx4032
AT narayandeepak incidenceofthev600kmutationamongmelanomapatientswithbrafmutationsandpotentialtherapeuticresponsetothespecificbrafinhibitorplx4032
AT halabanruth incidenceofthev600kmutationamongmelanomapatientswithbrafmutationsandpotentialtherapeuticresponsetothespecificbrafinhibitorplx4032
_version_ 1725769347005153280

Similar Items